<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en-GB">
	<id>https://haematologyetc.co.uk/index.php?action=history&amp;feed=atom&amp;title=ETP-ALL</id>
	<title>ETP-ALL - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://haematologyetc.co.uk/index.php?action=history&amp;feed=atom&amp;title=ETP-ALL"/>
	<link rel="alternate" type="text/html" href="https://haematologyetc.co.uk/index.php?title=ETP-ALL&amp;action=history"/>
	<updated>2026-04-27T14:59:03Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.39.0</generator>
	<entry>
		<id>https://haematologyetc.co.uk/index.php?title=ETP-ALL&amp;diff=4407&amp;oldid=prev</id>
		<title>John at 11:16, 4 January 2024</title>
		<link rel="alternate" type="text/html" href="https://haematologyetc.co.uk/index.php?title=ETP-ALL&amp;diff=4407&amp;oldid=prev"/>
		<updated>2024-01-04T11:16:38Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en-GB&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 13:16, 4 January 2024&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l1&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;----&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;div style=&quot;width: 200px&quot;&gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;{| class=&quot;wikitable&quot; style=&quot;border-left:solid 5px green;border-right:solid 5px green;border-top:solid 5px black;border-bottom:solid 5px black; font-size:90%; color:navy&quot;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;| colspan=&quot;1&quot;''|[[The flow cytometric diagnosis of AML|Return to previous page]]''&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;|}&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;/div&gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;----&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;ETPs are recent immigrants from the bone marrow (BM) to the thymus, derived from hematopoietic stem cells, which retain a certain level of multilineage pluripotency.7,8  By gene expression profiling, ETP cells share similarities with hematopoietic stem cells and myeloid progenitor cells.5  The definition of ETP-ALL/LBL is based on the immunophenotype of the leukemic cells, which are typically CD1a−, CD8−, CD5− (dim), and positive for 1 or more stem cell or myeloid antigens.5  In the World Health Organization (WHO) classification, ETP-ALL/LBL falls within the early T-ALL/LBL category. ETP ALL has been reported in 11% to 12% of childhood T-ALL/LBL5,9  and in 7.4% of adult T-ALL/LBL.9  ETP-ALL/LBL is also characterized by a distinct molecular profile with a lower incidence of NOTCH1 mutations and frequent presence of FLT3 and DNMT3A mutations.6,10-12&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;ETPs are recent immigrants from the bone marrow (BM) to the thymus, derived from hematopoietic stem cells, which retain a certain level of multilineage pluripotency.7,8  By gene expression profiling, ETP cells share similarities with hematopoietic stem cells and myeloid progenitor cells.5  The definition of ETP-ALL/LBL is based on the immunophenotype of the leukemic cells, which are typically CD1a−, CD8−, CD5− (dim), and positive for 1 or more stem cell or myeloid antigens.5  In the World Health Organization (WHO) classification, ETP-ALL/LBL falls within the early T-ALL/LBL category. ETP ALL has been reported in 11% to 12% of childhood T-ALL/LBL5,9  and in 7.4% of adult T-ALL/LBL.9  ETP-ALL/LBL is also characterized by a distinct molecular profile with a lower incidence of NOTCH1 mutations and frequent presence of FLT3 and DNMT3A mutations.6,10-12&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;ETP-ALL had a characteristic immunophenotype: CD1a and CD8-negative, CD5-negative, or dim (&amp;lt;75% of blasts positive) with one or more stem cell/myeloid markers positive (≥25% of blasts positive) (6). This served as the rationale for defining ETP-ALL under the latest WHO 2017 classification: positive intracytoplasmic CD3 expression and CD7 expression, CD1a-negative, CD8-negative, negative or dim expression of CD5 (&amp;lt;75% positive), and positive (≥25% of blasts population) for at least one stem cell or myeloid antigen, including CD34, HLA-DR, CD13, CD33, CD117, CD11b, and CD65 (4, 7). CD2 and CD4 may also be positive in ETP-ALL under the latest WHO 2017 classification (4).&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;ETP-ALL had a characteristic immunophenotype: CD1a and CD8-negative, CD5-negative, or dim (&amp;lt;75% of blasts positive) with one or more stem cell/myeloid markers positive (≥25% of blasts positive) (6). This served as the rationale for defining ETP-ALL under the latest WHO 2017 classification: positive intracytoplasmic CD3 expression and CD7 expression, CD1a-negative, CD8-negative, negative or dim expression of CD5 (&amp;lt;75% positive), and positive (≥25% of blasts population) for at least one stem cell or myeloid antigen, including CD34, HLA-DR, CD13, CD33, CD117, CD11b, and CD65 (4, 7). CD2 and CD4 may also be positive in ETP-ALL under the latest WHO 2017 classification (4).&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>John</name></author>
	</entry>
	<entry>
		<id>https://haematologyetc.co.uk/index.php?title=ETP-ALL&amp;diff=4405&amp;oldid=prev</id>
		<title>John at 11:02, 4 January 2024</title>
		<link rel="alternate" type="text/html" href="https://haematologyetc.co.uk/index.php?title=ETP-ALL&amp;diff=4405&amp;oldid=prev"/>
		<updated>2024-01-04T11:02:24Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en-GB&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 13:02, 4 January 2024&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l1&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;ETPs are recent immigrants from the bone marrow (BM) to the thymus, derived from hematopoietic stem cells, which retain a certain level of multilineage pluripotency.7,8  By gene expression profiling, ETP cells share similarities with hematopoietic stem cells and myeloid progenitor cells.5  The definition of ETP-ALL/LBL is based on the immunophenotype of the leukemic cells, which are typically CD1a−, CD8−, CD5− (dim), and positive for 1 or more stem cell or myeloid antigens.5  In the World Health Organization (WHO) classification, ETP-ALL/LBL falls within the early T-ALL/LBL category. ETP ALL has been reported in 11% to 12% of childhood T-ALL/LBL5,9  and in 7.4% of adult T-ALL/LBL.9  ETP-ALL/LBL is also characterized by a distinct molecular profile with a lower incidence of NOTCH1 mutations and frequent presence of FLT3 and DNMT3A mutations.6,10-12&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;ETPs are recent immigrants from the bone marrow (BM) to the thymus, derived from hematopoietic stem cells, which retain a certain level of multilineage pluripotency.7,8  By gene expression profiling, ETP cells share similarities with hematopoietic stem cells and myeloid progenitor cells.5  The definition of ETP-ALL/LBL is based on the immunophenotype of the leukemic cells, which are typically CD1a−, CD8−, CD5− (dim), and positive for 1 or more stem cell or myeloid antigens.5  In the World Health Organization (WHO) classification, ETP-ALL/LBL falls within the early T-ALL/LBL category. ETP ALL has been reported in 11% to 12% of childhood T-ALL/LBL5,9  and in 7.4% of adult T-ALL/LBL.9  ETP-ALL/LBL is also characterized by a distinct molecular profile with a lower incidence of NOTCH1 mutations and frequent presence of FLT3 and DNMT3A mutations.6,10-12&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;ETP-ALL had a characteristic immunophenotype: CD1a and CD8-negative, CD5-negative, or dim (&amp;lt;75% of blasts positive) with one or more stem cell/myeloid markers positive (≥25% of blasts positive) (6). This served as the rationale for defining ETP-ALL under the latest WHO 2017 classification: positive intracytoplasmic CD3 expression and CD7 expression, CD1a-negative, CD8-negative, negative or dim expression of CD5 (&amp;lt;75% positive), and positive (≥25% of blasts population) for at least one stem cell or myeloid antigen, including CD34, HLA-DR, CD13, CD33, CD117, CD11b, and CD65 (4, 7). CD2 and CD4 may also be positive in ETP-ALL under the latest WHO 2017 classification (4).&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>John</name></author>
	</entry>
	<entry>
		<id>https://haematologyetc.co.uk/index.php?title=ETP-ALL&amp;diff=4404&amp;oldid=prev</id>
		<title>John: Created page with &quot;ETPs are recent immigrants from the bone marrow (BM) to the thymus, derived from hematopoietic stem cells, which retain a certain level of multilineage pluripotency.7,8  By gene expression profiling, ETP cells share similarities with hematopoietic stem cells and myeloid progenitor cells.5  The definition of ETP-ALL/LBL is based on the immunophenotype of the leukemic cells, which are typically CD1a−, CD8−, CD5− (dim), and positive for 1 or more stem cell or myeloid...&quot;</title>
		<link rel="alternate" type="text/html" href="https://haematologyetc.co.uk/index.php?title=ETP-ALL&amp;diff=4404&amp;oldid=prev"/>
		<updated>2024-01-04T10:59:52Z</updated>

		<summary type="html">&lt;p&gt;Created page with &amp;quot;ETPs are recent immigrants from the bone marrow (BM) to the thymus, derived from hematopoietic stem cells, which retain a certain level of multilineage pluripotency.7,8  By gene expression profiling, ETP cells share similarities with hematopoietic stem cells and myeloid progenitor cells.5  The definition of ETP-ALL/LBL is based on the immunophenotype of the leukemic cells, which are typically CD1a−, CD8−, CD5− (dim), and positive for 1 or more stem cell or myeloid...&amp;quot;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;ETPs are recent immigrants from the bone marrow (BM) to the thymus, derived from hematopoietic stem cells, which retain a certain level of multilineage pluripotency.7,8  By gene expression profiling, ETP cells share similarities with hematopoietic stem cells and myeloid progenitor cells.5  The definition of ETP-ALL/LBL is based on the immunophenotype of the leukemic cells, which are typically CD1a−, CD8−, CD5− (dim), and positive for 1 or more stem cell or myeloid antigens.5  In the World Health Organization (WHO) classification, ETP-ALL/LBL falls within the early T-ALL/LBL category. ETP ALL has been reported in 11% to 12% of childhood T-ALL/LBL5,9  and in 7.4% of adult T-ALL/LBL.9  ETP-ALL/LBL is also characterized by a distinct molecular profile with a lower incidence of NOTCH1 mutations and frequent presence of FLT3 and DNMT3A mutations.6,10-12&lt;/div&gt;</summary>
		<author><name>John</name></author>
	</entry>
</feed>